Journal Mobile Options
Table of Contents
Vol. 72, No. 3-4, 2007
Issue release date: January 2008
Oncology 2007;72:164–171

Chemotherapy Use and Associated Factors among Cancer Patients near the End of Life

Yun Y.H. · Kwak M. · Park S.M. · Kim S. · Choi J.S. · Lim H.-Y. · Lee C.G. · Choi Y.S. · Hong Y.S. · Kim S.-Y. · Heo D.S.
aQuality of Cancer Care Branch, Research Institute for National Cancer Control and Evaluation, National Cancer Center, Goyang, bDivision of Hemato-Oncology, Department of Internal Medicine, Chungnam University Hospital, Daejeon, and cDepartment of Hemato-Oncology, Ulsan University College of Medicine, dDivision of Hematology-Oncology, Department of Internal Medicine, Samsung Medical Center, eDepartment of Radiation Oncology, Yonsei University College of Medicine, fDepartment of Family Medicine, Korea University College of Medicine, gDepartment of Medicine, Kangnam St. Mary’s Hospital, Catholic University of Korea, hDepartment of Medical Oncology and Hematology, Kyunghee University Hospital and iCancer Research Institute, Seoul National University College of Medicine, Seoul, Korea

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Objectives: We investigated the frequency of chemotherapy use and its associated factors in patients in all age groups in the last year of life. Methods: We identified cancer patients who died in 2004 in any of 17 hospitals. We used demographic and treatment characteristics by computerized hospital information systems and by linking the identification numbers to the 2004 death registry. Results: 48.7% of patients in the last 6 months of life, 43.9% in the last 3 months, and 30.9% in the last month of life received chemotherapy. The frequency of chemotherapy use was lower for older patients. In those ≧65 years old, there was no difference between women and men in the proportion that received chemotherapy. For patients <65 years of age, a larger proportion of women than men received chemotherapy, and chemotherapy use was significantly less frequent for patients with refractory disease than for those with responsive disease. Patients dying at a relatively small hospital without a hospice inpatient unit were significantly more likely to receive chemotherapy. Conclusions: Despite the fact that most cancer patients are resistant to chemotherapy at the end of life, it was administered often to all age groups.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Earle CC, Neville BA, Landrum MB, et al: Trends in the aggressiveness of cancer care near the end of life. J Clin Oncol 2004;22:315–321.
  2. von Gruenigen VE, Daly BJ: Futility: clinical decisions at the end-of-life in women with ovarian cancer. Gynecol Oncol 2005;97:638–644.
  3. Emanuel LL, von Gunten CF, Ferris FD: Gaps in end-of-life care. Arch Fam Med 2000;9:1176–1180.
  4. Emanuel EJ, Young-Xu Y, Levinsky NG, et al: Chemotherapy use among Medicare beneficiaries at the end of life. Ann Intern Med 2003;138:639–643.
  5. Gagnon B, Mayo NE, Hanley J, et al: Pattern of care at the end of life: does age make a difference in what happens to women with breast cancer? J Clin Oncol 2004;22:3458–3465.
  6. Bach PB, Schrag D, Begg CB: Resurrecting treatment histories of dead patients: a study design that should be laid to rest. JAMA 2004;292:2765–2770.
  7. Earle CC, Venditti LN, Neumann PJ, et al: Who gets chemotherapy for metastatic lung cancer? Chest 2000;117:1239–1246.
  8. Potosky AL, Riley GF, Lubitz JD, et al: Potential for cancer related health services research using a linked Medicare-tumor registry database. Med Care 1993;31:732–748.
  9. Cancer care during the last phase of life. American Society of Clinical Oncology. J Clin Oncol 1998;16:1986–1996.
  10. Rubin DB: Estimating causal effects from large data sets using propensity scores. Ann Intern Med 1997;127:757–763.
  11. Cohen J: Statistical Power Analysis for the Behavioral Sciences, ed 2. Hillsdale, Erlbaum, 1988.
  12. Aabom B, Kragstrup J, Vondeling H, et al: Defining cancer patients as being in the terminal phase: who receives a formal diagnosis, and what are the effects? J Clin Oncol 2005;23:7411–7416.
  13. Giordano SH, Hortobagyi GN, Kau SW, et al: Breast cancer treatment guidelines in older women. J Clin Oncol 2005;23:783–791.
  14. Schulman KA, Berlin JA, Harless W, et al: The effect of race and sex on physicians’ recommendations for cardiac catheterization. N Engl J Med 1999;340:618–626.
  15. Bruera E, Russell N, Sweeney C, et al: Place of death and its predictors for local patients registered at a comprehensive cancer center. J Clin Oncol 2002;20:2127–2133.
  16. Gallo WT, Baker MJ, Bradly EH: Factors associated with home versus institutional death among cancer patients in Connecticut. J Am Geriatr Soc 2001;49:771–777.
  17. Browner I, Carducci MA: Palliative chemotherapy: historical perspective, applications, and controversies. Semin Oncol 2005;32:145–155.
  18. Doyle C, Crump M, Pintilie M, et al: Does palliative chemotherapy palliate? Evaluation of expectations, outcomes, and costs in women receiving chemotherapy for advanced ovarian cancer. J Clin Oncol 2001;19:1266–1274.
  19. Grunfeld EA, Maher EJ, Browne S, et al: Advanced breast cancer patients’ perceptions of decision making for palliative chemotherapy. J Clin Oncol 2006;24:1090–1098.
  20. Lunney JR, Lynn J, Foley DJ, et al: Patterns of functional decline at the end of life. JAMA 2003;289:2387–2392.
  21. Lubitz JD, Riley GF: Trends in Medicare payments in the last year of life. N Engl J Med 1993;328:1092–1096.
  22. Yun YH, Heo DS, Bae JM, et al: Retrospective cohort study of survival and prognostic factors in patients with terminal cancer. J Korean Cancer Assoc 1998;30:188–198.
  23. Glare PA, Eychmueller S, McMahon P: Diagnostic accuracy of the palliative prognostic score in hospitalized patients with advanced cancer. J Clin Oncol 2004;22:4823–4828.
  24. Malin JL: Bridging the divide: integrating cancer-directed therapy and palliative care. J Clin Oncol 2004;22:3438–3440.
  25. Elsayem A, Swint K, Fisch MJ, et al: Palliative care inpatient service in a comprehensive cancer center: clinical and financial outcomes. J Clin Oncol 2004;22:2008–2014.
  26. McCusker J: The terminal period of cancer: definition and descriptive epidemiology. J Chronic Dis 1984;37:377–385.
  27. Earle CC, Emanuel EJ: Patterns of care studies: creating ‘an environment of watchful concern’. J Clin Oncol 2003;21:4479–4480.
  28. Browner I, Carducci MA: Palliative chemotherapy: historical perspective, applications, and controversies. Semin Oncol 2005;32:145–155.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50